Jennison Associates LLC Corvus Pharmaceuticals, Inc. Transaction History

Jennison Associates LLC

  • $160 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

Apr 20, 2018
SELL
$7.48 - $11.53 $3.49 Million - $5.38 Million
-466,724 Closed
0 $0
Q4 2017

Jan 25, 2018
SELL
$9.3 - $16.93 $3.96 Million - $7.21 Million
-425,927 Reduced 47.71%
466,724 $4.84 Million
Q3 2017

Nov 03, 2017
BUY
$11.3 - $17.23 $10.1 Million - $15.4 Million
892,651
892,651 $14.2 Million

Others Institutions Holding CRVS

# of Institutions
73
Shares Held
30.4M
Call Options Held
1.06M
Put Options Held
84.3K
View Full List

About Corvus Pharmaceuticals, Inc.

CRVS Quotes by TradingView
  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $417M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email